Quote from VigiServe Admin on January 29, 2026, 2:22 PM

The pharmacovigilance (PV) system in Antigua and Barbuda is emerging and basic, characteristic of many small Caribbean island nations. It aligns with WHO minimum requirements for national PV systems but lacks detailed, codified national regulations comparable to ICH/EU or even more developed regional systems (e.g., Algeria or Pakistan). Antigua and Barbuda is an associate member of the WHO Programme for International Drug Monitoring (PIDM), preparing for full membership, and contributes (or aims to contribute) adverse drug reaction (ADR) reports to the global VigiBase database via WHO channels.

The system relies heavily on regional support from the Caribbean Public Health Agency (CARPHA) and the Caribbean Regulatory System (CRS), including the VigiCarib online platform (launched 2017) for ADR and substandard/falsified product reporting across participating Caribbean countries. Reporting is encouraged but volumes remain low due to limited infrastructure, awareness, and resources.

Legal Framework and Governance

• Overseen by the Ministry of Health, Wellness and the Environment (via the Pharmaceutical Division and Pharmacy Council under the Pharmacy Act 1995).
• The Pharmacy Council ensures medicine safety, efficacy, and quality per international standards, with inspectors enforcing compliance.
• No dedicated national pharmacovigilance center or standalone Good Pharmacovigilance Practices (GVP) guide is publicly detailed; activities follow WHO guidelines and CARPHA/CRS regional frameworks.
• Focus on spontaneous ADR reporting, surveillance for medicine-related risks, and collaboration with CARPHA for training, data sharing, and subregional monitoring.

Organization and Personnel

• Marketing Authorization Holders (MAHs), importers, distributors, or local representatives are expected to monitor product safety and report ADRs.
• No mandatory requirement for a local Qualified Person for Pharmacovigilance (QPPV), Local QPPV, or dedicated PV contact residing in the country.
• Healthcare professionals (HCPs), hospitals, and public health programs drive most reporting; companies support via internal processes.

PV System Master File (PSMF) No formal requirement for a PSMF or its registration/location.

Individual Case Safety Reports (ICSRs) – Post-Marketing

• Suspected ADRs reported voluntarily by HCPs, patients, or companies to the Ministry of Health, Pharmacy Council, or via VigiCarib (secure web application requiring registration).
• No strict expedited timelines (e.g., 15 days for serious) codified nationally; follows general WHO expectations for prompt reporting of serious/unexpected events to support signal detection.
• Standardized forms or VigiCarib tools used; emphasis on spontaneous reporting with regional CARPHA support.

Periodic Benefit-Risk Evaluation Reports (PBRER/PSUR) No routine mandatory periodic submissions specified. Safety updates may be requested during registration/renewals or safety concerns, potentially aligned with WHO or regional formats.

Risk Management Plans (RMP) Not a standard mandatory requirement; risk assessment handled reactively through national/regional surveillance.

Signal Management and Emerging Safety Issues

• Ongoing monitoring via Ministry/CARPHA channels.
• Significant issues (e.g., new risks, foreign actions) should be notified promptly, though no fixed timelines detailed publicly.

Clinical Trials-Related Safety Requirements Clinical trials in Antigua and Barbuda are limited (small population, infrastructure constraints); most are small-scale, hospital-based, or part of multi-country studies, authorized by the Ministry of Health and ethics committees.

• Sponsors must monitor safety and report serious adverse events, including Suspected Unexpected Serious Adverse Reactions (SUSARs) or equivalent.
• No dedicated national electronic system (e.g., no EudraVigilance/CTIS access); reports submitted directly to the Ministry of Health or relevant authorities (often via email/forms).
• Timelines align with international/WHO norms: expedited for serious unexpected events (typically 7-15 days, faster for fatal/life-threatening), though not explicitly codified beyond general ADR/PV expectations.
• Periodic/Development Safety Update Reports (DSURs) may be required or requested, following ICH E2F/WHO formats, especially for ongoing or multi-site trials.
• Sponsor responsibility emphasized for monitoring, causality assessment, and communication to authorities/ethics bodies.

Additional Monitoring / Other Aspects

• No black triangle/additional monitoring scheme.
• Strong regional emphasis via CARPHA/CRS on vaccine/medicines safety, counterfeit detection, and training to build capacity.
• Inspections/audits possible via Pharmacy Council; low ADR reporting due to awareness/resource gaps, but VigiCarib and WHO support aim to improve.

Antigua and Barbuda's PV framework is functional at a minimal level, prioritizing WHO/CARPHA-aligned surveillance and regional collaboration over stringent MAH obligations (no QPPV/PSMF/RMP mandates or detailed timelines). It focuses on practical post-marketing vigilance in a small-market context. For precise, product- or trial-specific requirements (e.g., imports, clinical studies), consult the Ministry of Health directly (health.gov.ag or Pharmaceutical Division contacts) or CARPHA (carpha.org for VigiCarib guidance), as systems evolve with regional/WHO initiatives. Companies often align with WHO minimums or reference larger systems (e.g., US FDA, EU) for operations in the country.